Minding the London Stock Exchange’s Business
Independent and Fearless Financial Journalism Funded by Readers
Even a few of our detractors have now come around
“Microsaic Systems plc (MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its unaudited interim results for the six months ended 30 June 2020 and an update on trading since the period end”. Encouraging then?...
Previously writing on Microsaic Systems (MSYS), in March with the shares at 0.80p I concluded it’s not the board’s belief which is important here and note the fundraising is required following the above financials and from a current £3.65 million market cap. Readers here should not be surprised by this latest and, natch, currently the stance remains avoid / sell. Now a “Strategic Review and Formal Sale Process” announcement – and the shares 0.35p...
“Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its audited financial results for the year ended 31 December 2019”. The shares have currently responded to 0.80p – 20% lower!…
Microsaic Systems (MSYS) “is pleased to announce the appointment of WH Ireland Limited as Joint Broker with immediate effect, alongside N+1Singer as Nominated Adviser and Joint Broker”. Hmmm – I wonder why?...
Previously writing on developer of mass spectrometry instruments Microsaic Systems (MSYS) it was with the company arguing “encouraged with the progress made in the first half” but the shares down to 1.15p. They have since fallen further and today a “Global collaboration agreement with Axcend Corp”…
“Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its unaudited interim results for the six months ended 30 June 2019”. The shares have currently responded to 1.15p – er, more than 25% lower!...
An intra-day (11:20am) “Bioprocessing partnership update & trading update” from mass spectrometry instruments developer Microsaic Systems (MSYS). This firstly “confirms that trading in 2018 remains in line with the board's expectations” and then that phase two of the partnership “with a global partner in bioprocessing… has now been completed successfully, with a clear addressable market identified and positive feedback received from potential customers”. So why a 25% share price fall, towards 1p?...
